MAPK8 and small cell lung carcinoma: Treatment of human small cell lung cancer (SCLC) cell with doxorubicin at 50 nM increased c-jun N-terminal kinase (JNK) activity and simultaneously induced a markedly increase in MRP1 expression [30].